News
NVS
157.59
+1.40%
2.18
Weekly Report: what happened at NVS last week (0622-0626)?
Weekly Report · 17h ago
FDA set to review Sandoz's generic GLP-1s
Reuters · 17h ago
Harbour BioMed appoints Lloyd Klickstein scientific advisor for immunology
PUBT · 1d ago
Can Biogen's New Drugs Revive Growth Amid Legacy Sales Slump?
NASDAQ · 3d ago
The Zacks Analyst Blog Highlights JPMorgan, Novartis, Qualcomm, Genie and ImmuCell
NASDAQ · 3d ago
Top Stock Reports for JPMorgan, Novartis & Qualcomm
NASDAQ · 4d ago
Novartis Plays Long Game With Antares Deal - Meaning Near-Term Upside Unlikely
Seeking Alpha · 4d ago
Novartis: Buy Rating Reiterated on Pelacarsen Cardiovascular Upside; $135 Price Target Unchanged
TipRanks · 4d ago
Is GSK Quietly Becoming An Oncology Powerhouse
Seeking Alpha · 4d ago
Deutsche Bank Sticks to Their Buy Rating for Novartis AG (NOVN)
TipRanks · 4d ago
Candel Therapeutics names Mark Sims chief commercial officer
PUBT · 4d ago
Shanghai Henlius says first US patient dosed in Phase 1 trial of ipilimumab biosimilar HLX13 for advanced liver cancer
PUBT · 4d ago
ANALYSIS-US prices for new drugs fell in 2025 as fewer costly gene therapies were launched
Reuters · 4d ago
TCW Relative Value Large Cap Fund Q1 2026 Buys And Sells
Seeking Alpha · 5d ago
BioAge Labs: Developing A 'Pipeline In A Pill'
Seeking Alpha · 5d ago
Novartis, Antares Partner To Pursue Undruggable Cancer Targets In $1.9 Billion Deal
Benzinga · 5d ago
Novartis and Antares to develop cancer drugs in a deal worth up to $1.9B
Seeking Alpha · 5d ago
Vertex Pharmaceuticals: Povetacicept May Redefine Growth Narrative (Rating Upgrade)
Seeking Alpha · 5d ago
Antares Therapeutics Partners With Novartis To Discover, Develop, Commercialize Small Molecule Therapies To Treat Undruggable Oncology Targets; Antares To Receive $105M Upfront Payment
Benzinga · 5d ago
Pre-Market Most Active for Jun 24, 2026 : WEN, NOK, ABSI, RUN, SQQQ, SPCX, CCXI, NVS, NIO, INFQ, AMC, SMR
NASDAQ · 5d ago
More
Webull provides a variety of real-time NVS stock news. You can receive the latest news about Novartis through multiple platforms. This information may help you make smarter investment decisions.
About NVS
Novartis AG is a Switzerland-based pharmaceutical company. The Company develops, manufactures, and markets branded and generic prescription drugs, active pharmaceutical ingredients (APIs), biosimilars and ophthalmic products. The Company uses science and digital technologies for treatments in the disease areas of immunology, dermatology, cancer, ophthalmology, neuroscience, respiratory, cardiovascular, renal and metabolism. The business activities of the Company are divided into two segments: Innovative Medicines, which includes innovative patent-protected prescription medicines for blood pressure, cancer and other ailments, and Sandoz, which includes generic pharmaceuticals and biosimilars.